Corvus Pharmaceuticals will announce interim Phase 1 trial data for soquelitinib in atopic dermatitis on December 18, 2024.
Quiver AI Summary
Corvus Pharmaceuticals, Inc. will release interim data from its Phase 1 clinical trial of soquelitinib for patients with moderate to severe atopic dermatitis on December 18, 2024. The data will be shared through a press release and a conference call at 8:00 a.m. ET, accessible via phone and webcast from the company's website. Soquelitinib, an oral investigational drug that selectively inhibits interleukin-2-inducible T cell kinase (ITK), is being studied for its potential therapeutic benefits in various cancers and autoimmune diseases by influencing T cell differentiation. Corvus is also advancing a Phase 3 clinical trial of soquelitinib for relapsed peripheral T cell lymphoma, following positive preliminary outcomes in refractory T cell lymphoma trials. The company is positioned at the forefront of developing ITK inhibition as a novel immunotherapy approach.
Potential Positives
- Announcement of interim data from a Phase 1 clinical trial for soquelitinib demonstrates transparency and active communication with stakeholders.
- Positive interim results in addressing moderate to severe atopic dermatitis could signify a new treatment option in a significant medical market.
- Previous favorable outcomes in T cell lymphoma trials strengthen the credibility of soquelitinib and Corvus Pharmaceuticals as a leader in immunotherapy.
- The company showcases its commitment to research and development with a focus on innovative therapeutic approaches through ITK inhibition.
Potential Negatives
- Presents interim data rather than conclusive results, which may raise concerns about the efficacy and safety of soquelitinib.
- The company's reliance on an investigational drug suggests uncertainty in achieving successful clinical outcomes, given the complexity of treating conditions like atopic dermatitis.
- Pending data release could create volatility in stock price and investor sentiment, particularly if results do not meet market expectations.
FAQ
When will Corvus Pharmaceuticals announce interim data?
Corvus Pharmaceuticals will announce interim data on December 18, 2024.
What is soquelitinib being tested for?
Soquelitinib is being tested for moderate to severe atopic dermatitis in a Phase 1 clinical trial.
How can I access the conference call and webcast?
The conference call can be accessed by calling 1-800-717-1738 or 1-646-307-1865, or via the Corvus website.
What type of drug is soquelitinib?
Soquelitinib is an investigational small molecule drug that selectively inhibits ITK, used in immunotherapy.
How long will the webcast replay be available?
The replay of the webcast will be available for 60 days on the Corvus website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRVS Hedge Fund Activity
We have seen 35 institutional investors add shares of $CRVS stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SAMLYN CAPITAL, LLC removed 1,592,688 shares (-26.0%) from their portfolio in Q3 2024
- VIVO CAPITAL, LLC added 1,497,268 shares (+inf%) to their portfolio in Q3 2024
- VANGUARD GROUP INC added 770,119 shares (+46.7%) to their portfolio in Q3 2024
- GHOST TREE CAPITAL, LLC added 500,000 shares (+inf%) to their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. removed 401,781 shares (-6.7%) from their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC added 376,121 shares (+inf%) to their portfolio in Q3 2024
- BVF INC/IL removed 361,406 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call and webcast.
Conference Call, Webcast and Presentation Slides
Corvus will host a conference call and webcast tomorrow, Wednesday, December 18, 2024 at 8:00 a.m. ET / 5:00 a.m. PT to provide an overview of the soquelitinib atopic dermatitis Phase 1 clinical data. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on
this link
for telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the
investor relations
section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 60 days.
About Soquelitinib
Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation which has the potential to suppress autoimmune and inflammatory reactions. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company has initiated a registrational Phase 3 clinical trial (
NCT06561048
) of soquelitinib in patients with relapsed peripheral T cell lymphoma. Soquelitinib is also now being investigated in a randomized placebo-controlled phase 1 clinical trial in patients with atopic dermatitis. A recent publication describing the chemistry, enzymology and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the
Nature
website and on the
Publications and Presentations
page of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit
www.corvuspharma.com
.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
